Anticancer activity of TTAC-0001, a fully human anti-vascular endothelial growth factor receptor 2 (VEGFR-2/KDR) monoclonal antibody, is associated with inhibition of tumor angiogenesis

Ítems similars

• TTAC-0001, a human monoclonal antibody targeting VEGFR-2/KDR, blocks tumor angiogenesis
  per: Lee, Weon Sup, et al.
  Publicat: (2015)
• Preclinical pharmacokinetics, interspecies scaling, and pharmacokinetics of a Phase I clinical trial of TTAC-0001, a fully human monoclonal antibody against vascular endothelial growth factor 2
  per: Lee, Weon Sup, et al.
  Publicat: (2018)
• Evaluation of drug mechanism and efficacy of a novel anti-angiogenic agent, TTAC-0001, using multi-modality bioimaging in a mouse breast cancer orthotopic model
  per: Kim, Jinil, et al.
  Publicat: (2018)
• ACTR-75. A MULTICENTER, 3-ARM, OPEN-LABEL, PHASE IIA CLINICAL TRIAL TO EVALUATE SAFETY AND EFFICACY OF TANIBIRUMAB (VEGFR2 MAB), IN PATIENTS WITH RECURRENT GBM ASSESSED WITH K-TRANS AND INITIAL AREA UNDER THE GADOLINIUM CONCENTRATION-TIME CURVE (IAUGC)
  per: Cher, Lawrence, et al.
  Publicat: (2017)
• Intravitreal Tanibirumab, a Fully Human Monoclonal Antibody Against Vascular Endothelial Growth Factor Receptor 2, Partially Suppresses and Regresses Laser-Induced Choroidal Neovascularization in a Rat Model
  per: Kim, Jaeryung, et al.
  Publicat: (2014)